Format

Send to

Choose Destination
See comment in PubMed Commons below
Onco Targets Ther. 2013 Jun 18;6:733-40. doi: 10.2147/OTT.S46135. Print 2013.

Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.

Author information

1
Hematology Department, Affiliated Hospital of Chengde Medical College, Chengde, Hebei Province, People's Republic of China.

Abstract

The chimeric fusion protein, AML1-ETO, generated by translocation of t(8;21), abnormally recruits histone deacetylase (HDAC) to the promoters of AML1 target genes, resulting in transcriptional repression of the target genes and development of t(8;21) acute myeloid leukemia. Abnormal expression of cyclin-dependent kinase inhibitors, especially p21, is considered a possible mechanism of the arrested maturation and differentiation seen in leukemia cells. A new generation of HDAC inhibitors is becoming an increasing focus of attention for their ability to induce differentiation and apoptosis in tumor cells and to block the cell cycle. Our previous research had demonstrated that valproic acid induces G0/G1 arrest of Kasumi-1 cells in t(8;21) acute myeloid leukemia. In this study, we further confirmed that valproic acid inhibits the growth of Kasumi-1 cells in a murine xenograft tumor model, and that this occurs via upregulation of histone acetylation in the p21 promoter region, enhancement of p21 expression, suppression of phosphorylation of retinoblastoma protein, blocking of transcription activated by E2F, and induction of G0/G1 arrest.

KEYWORDS:

AML1-ETO; E2F; acute myeloid leukemia; p21; valproic acid

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center